ATE310512T1 - Verwendung von lipoxinen zur inhibierung von tnf- alpha initiierter gegenreaktion - Google Patents

Verwendung von lipoxinen zur inhibierung von tnf- alpha initiierter gegenreaktion

Info

Publication number
ATE310512T1
ATE310512T1 AT00917903T AT00917903T ATE310512T1 AT E310512 T1 ATE310512 T1 AT E310512T1 AT 00917903 T AT00917903 T AT 00917903T AT 00917903 T AT00917903 T AT 00917903T AT E310512 T1 ATE310512 T1 AT E310512T1
Authority
AT
Austria
Prior art keywords
lipoxins
initiated
counterreaction
alpha
inhibit tnf
Prior art date
Application number
AT00917903T
Other languages
German (de)
English (en)
Inventor
Charles N Serhan
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE310512T1 publication Critical patent/ATE310512T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT00917903T 1999-03-18 2000-03-14 Verwendung von lipoxinen zur inhibierung von tnf- alpha initiierter gegenreaktion ATE310512T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12520599P 1999-03-18 1999-03-18
PCT/US2000/006582 WO2000054767A1 (en) 1999-03-18 2000-03-14 Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response

Publications (1)

Publication Number Publication Date
ATE310512T1 true ATE310512T1 (de) 2005-12-15

Family

ID=22418647

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00917903T ATE310512T1 (de) 1999-03-18 2000-03-14 Verwendung von lipoxinen zur inhibierung von tnf- alpha initiierter gegenreaktion

Country Status (11)

Country Link
US (6) US6387953B1 (https=)
EP (1) EP1165066B1 (https=)
JP (1) JP4440481B2 (https=)
AT (1) ATE310512T1 (https=)
AU (1) AU775140B2 (https=)
CA (3) CA2615917C (https=)
DE (1) DE60024242T2 (https=)
DK (1) DK1165066T3 (https=)
ES (1) ES2249257T3 (https=)
HK (1) HK1043307B (https=)
WO (1) WO2000054767A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
CA2675416A1 (en) * 1999-03-18 2000-09-21 Brigham And Women's Hospital Lipoxin compounds and their use
ES2249257T3 (es) * 1999-03-18 2006-04-01 The Brigham And Women's Hospital, Inc. Utilizacion de compuestos de lipoxina para la inhibicion de la respuesta de los neutrofilos inducida por tnf-alfa.
AU780114B2 (en) 1999-03-18 2005-03-03 Brigham And Women's Hospital Regulation of phospholipase D activity
JP4932116B2 (ja) 2000-02-16 2012-05-16 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アスピリン誘発脂質メディエータ
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
GB2362140B (en) * 2000-05-12 2003-03-05 Autoliv Dev Improvements in or relating to an apparatus for a method of folding an air-bag
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
PT1406698E (pt) * 2001-03-02 2009-01-12 Brigham & Womens Hospital Análogos de lipoxina como novos inibidores da angiogénese
EP1911448B1 (en) * 2001-11-06 2013-01-02 The Brigham and Women's Hospital, Inc. Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
JP4652685B2 (ja) * 2001-11-06 2011-03-16 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 喘息および炎症性気道疾患の治療におけるリポキシンおよびアスピリン誘発リポキシンおよびそれらの安定な類似物
US6831186B2 (en) 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
WO2003051350A1 (en) * 2001-12-18 2003-06-26 The Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
DE60330154D1 (de) * 2002-08-12 2009-12-31 Brigham & Womens Hospital Resolvine: biotemplate zur durchführung therapeutischer anwendungen
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
AU2005216298B2 (en) 2004-02-26 2010-09-02 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
US20050238589A1 (en) * 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
US8273792B2 (en) 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
US8636986B2 (en) * 2005-11-18 2014-01-28 The Forsyth Institute Treatment and prevention of bone loss using resolvins
PE20120395A1 (es) 2006-12-04 2012-05-23 Bayer Ip Gmbh Sal de potasio cristalina de analogos de lipoxina a4
WO2011050126A1 (en) * 2009-10-21 2011-04-28 University Of Medicine And Dentistry Of New Jersey Method for treating sepsis or septic shock
WO2018144316A1 (en) 2017-01-31 2018-08-09 The Brigham And Women's Hospital, Inc. Alx receptor ligands define a biochemical endotype for inflammation-based diseases
US20220040136A1 (en) 2018-10-09 2022-02-10 University Of Rochester Treatment of vulvovaginal disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08512023A (ja) * 1993-06-15 1996-12-17 ブリガム・アンド・ウイメンズ・ホスピタル リポキシン化合物
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
WO1995001179A1 (en) * 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
CA2675416A1 (en) * 1999-03-18 2000-09-21 Brigham And Women's Hospital Lipoxin compounds and their use
AU780114B2 (en) * 1999-03-18 2005-03-03 Brigham And Women's Hospital Regulation of phospholipase D activity
ES2249257T3 (es) * 1999-03-18 2006-04-01 The Brigham And Women's Hospital, Inc. Utilizacion de compuestos de lipoxina para la inhibicion de la respuesta de los neutrofilos inducida por tnf-alfa.

Also Published As

Publication number Publication date
US6703423B2 (en) 2004-03-09
US6387953B1 (en) 2002-05-14
US20080312323A1 (en) 2008-12-18
US20040192785A1 (en) 2004-09-30
CA2615917C (en) 2011-10-04
US20080081838A1 (en) 2008-04-03
US20020132847A1 (en) 2002-09-19
CA2615917A1 (en) 2000-09-21
JP2002539159A (ja) 2002-11-19
HK1043307B (en) 2006-02-03
AU3880600A (en) 2000-10-04
ES2249257T3 (es) 2006-04-01
EP1165066A1 (en) 2002-01-02
HK1043307A1 (en) 2002-09-13
CA2747376A1 (en) 2000-09-21
WO2000054767A1 (en) 2000-09-21
DE60024242D1 (de) 2005-12-29
AU775140B2 (en) 2004-07-22
CA2367909C (en) 2008-02-12
EP1165066B1 (en) 2005-11-23
US6710084B2 (en) 2004-03-23
JP4440481B2 (ja) 2010-03-24
US7132451B2 (en) 2006-11-07
CA2367909A1 (en) 2000-09-21
US20020143069A1 (en) 2002-10-03
DE60024242T2 (de) 2006-12-14
DK1165066T3 (da) 2006-03-06

Similar Documents

Publication Publication Date Title
ATE310512T1 (de) Verwendung von lipoxinen zur inhibierung von tnf- alpha initiierter gegenreaktion
BG108492A (bg) Използване на въглероден окис за подобряване на резултатите при трансплантация на тъкани и органи и потискане на апоптозата
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
DE60217367D1 (de) Nanopartikelzusammensetzungen enthaltend insulin
PH12016500941A1 (en) Protection, restoration, and enhancement for erythropoietin-responsive cells, tissues and organs
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
WO2003050271A3 (en) In vitro production of dendritic cells from cd14+ monocytes
ES2102196T3 (es) Periferializacion de celulas pluripotenciales hematopoyeticas.
DK1007082T3 (da) Modificeret tumor nekrose faktor
PT1062321E (pt) Utilizacoes para celulas estaminais mesenquimais humanas nao autologas
DE59308257D1 (de) 25-carbonsäure-derivate in der vitamin d-reihe, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
ATE90345T1 (de) Bis-naphthalimide, ihre herstellung und verwendung.
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
Khuituan et al. Fibroblast growth factor-23 negates 1, 25 (OH) 2D3-induced intestinal calcium transport by reducing the transcellular and paracellular calcium fluxes
DE60023660D1 (de) Antizymmodulatoren sowie deren verwendung
YU19399A (sh) Lokalni anestetik za spoljnu upotrebu
IT1271301B (it) Calconi naturali e sintetici e loro esteri ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno e formulazioni che li contengono
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
IL156628A (en) Use of nk t cells in medical preparation, preparations containing nk t cells and their use in the treatment of immune-related disorders
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
BR0308810A (pt) Células hospedeiras tendo propriedades melhoradas de sobrevivência celular e métodos para gerar tais células
ES2154311T3 (es) Quinoxalinas, procedimiento para su preparacion y su utilizacion.
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165066

Country of ref document: EP